Securities code: 002432 securities abbreviation: Andon Health Co.Ltd(002432) Announcement No.: 2022-011 Andon Health Co.Ltd(002432)
Stock trading risk warning announcement
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and shall be jointly and severally liable for false records, misleading statements or major omissions in the announcement. Important:
Recently, the shares of Andon Health Co.Ltd(002432) (hereinafter referred to as the “company”) (Securities abbreviation: Andon Health Co.Ltd(002432) , securities code: 002432) fluctuated greatly. The company was established in December 2021
On January 31 and January 13, 2022, the announcement on abnormal fluctuation of stock trading and risk warning was disclosed twice. Please pay attention to the investment risk.
1、 Risk tips
Please note that the single month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance. The company believes that it is necessary to give another risk prompt, as follows:
1. Risk of uncertainty in the development of the epidemic situation in the United States: the demand for the company’s antigen home self-test kit products is directly related to the development of the epidemic situation in the United States. Virus variation, vaccination and the introduction of covid-19 drugs all have an impact on the development of the epidemic situation. Therefore, the development of the epidemic situation in the future has strong uncertainty, This uncertainty may greatly affect the demand of kit products;
2. Uncertainty risk of market competition: at present, the household self-test kit products of 12 companies have been approved
With the authorization of FDA EUA, it cannot be ruled out that more companies will obtain the authorization and enter the market to sell kit products in the future. With the change of market competition situation, the existing market share and product price of a single enterprise may be impacted;
3. Rationality risk of valuation model: the sales of the company’s kit products are highly related to the development of the epidemic situation, and the trend of the epidemic situation is difficult to predict, so the long-term impact of the product on the company’s fundamentals is also difficult to predict. Investors should pay attention to the rationality of the stock price combined with their own valuation model, and there are many factors affecting the stock price in the secondary market. Investors should pay attention to investment risk, Rational investment;
4. Reliability risk of information: the company’s answers on the interactive platform are based on the company’s disclosed information, Amazon America’s information and public information. There is no compilation without objective basis
Disclose in any form the information required to be disclosed in the information disclosure regulations of listed companies and not yet disclosed, especially the information related to production, sales, sales and so on. Investors are requested to follow the official information released by the company, do not believe the rumors, and do not presumptuously calculate the sales data and profits of the company’s kit products, resulting in miscalculation and investment loss;
5. Exchange rate fluctuation risk: the company’s kit products are settled in US dollars; With the expansion of sales scale, the amount of foreign currency held by the company will further increase. In view of the uncertainty of exchange rate fluctuations, the company will adjust the product sales price accordingly according to the exchange rate changes, and will consider locking the exchange rate by signing relevant agreements with banks to prevent the risk of large exchange rate fluctuations. However, if the fluctuation range is large in the short term, the company may have exchange losses, which will have an adverse impact on the company’s operating performance;
6. Trade risk to the United States: in terms of trade with the United States, some products of the company are affected by the additional tariff imposed by the United States. Although the proportion of such products is relatively small, if the tariff policy of the United States is further tightened, it may lead to the reduction of the company’s total sales and profits to the United States. In order to cope with the above risks, the company will continue to pay attention to the changes in the international trade situation and adjust its sales and pricing strategies in a timely manner;
7. Logistics and transportation risk: due to the epidemic situation in the United States, the current shortage of transport capacity in air and sea channels continues, port congestion and serious backlog of goods. If the shipped goods cannot be picked up in time, it will have an adverse impact on product sales;
8. Quality risk: in the case of mass production, the batches of individual products may have quality problems, leading to the risk of return or even recall.
In addition, the company also needs to remind investors of the following situations:
1. In the previous announcement, the company mentioned the epidemic prevention related plans issued by the U.S. government, as well as the relevant policies, procurement and distribution plans and conditions of covid-19 antigen household self-test kit products. Investors are reminded that the relevant information and procurement involved in the above contents are not only for the company. Investors are requested not to misunderstand the contents and misinfer the changes it brings to the company’s performance.
2. The sales information disclosed by the company in the previous announcement cannot represent the profit. Because the profit is related to many factors such as raw material cost, product transportation cost, production and manufacturing cost, sales cost, management cost and R & D cost, it is impossible to calculate the profit from the sales amount. Please pay attention to the subsequent announcement of the company for the relevant information of the company’s performance.
3. At present, the company’s share price is at an all-time high, and the risk of falling in the future cannot be ruled out. The company hereby reminds investors that the company will strictly implement the relevant provisions on information disclosure of listed companies and timely fulfill the obligation of information disclosure. It also takes this opportunity to remind investors again that there are many rumors on the Internet platform. Investors are requested to take the information officially released by the company as the standard and do not calculate the company’s performance and future trend without basis. There are many factors affecting the stock price of the secondary market, and the development of the epidemic in the United States in the future is still uncertain. The sales of kit products are affected by many factors. Investors are invited to pay attention to investment risks and invest rationally.
4. The company previously submitted the proposal on using family self-test box to realize Omicron covid-19 epidemic prevention 1 + 1 to Tianjin epidemic prevention and control headquarters. At present, relevant departments are studying the proposal, and it is uncertain whether the proposal will be adopted.
Please correctly interpret the above contents, pay attention to risks and invest rationally.
It is hereby announced
Andon Health Co.Ltd(002432) board of directors
January 14, 2022
